Sepsis Diagnostics Market To Reach USD 1,392.8 Million By 2032

Introduction

Global Sepsis Diagnostics Market Size is expected to be worth around USD 1392.8 Million by 2032, from USD 682.1 Million in 2023, growing at a CAGR of 8.5% during the forecast period from 2023 to 2032. In 2023, North America led the market, achieving over 41% share with a revenue of USD 257.7 Million.

The market is propelled by the urgent need for quick and precise sepsis diagnosis and management. The recent updates to the Surviving Sepsis Campaign guidelines are crucial, promoting the rapid use of antibiotics and enhanced monitoring of organ functions. These guidelines are critical in improving patient outcomes by focusing on quick diagnostic procedures.

Central to the market’s growth are innovative diagnostic technologies. For example, the guidelines suggest dynamic fluid resuscitation measures, necessitating advanced equipment to measure intravascular volume and organ perfusion accurately. Moreover, involving patients and families in care, alongside the integration of telehealth services, supports a patient-centered approach in managing sepsis, gaining further relevance during the COVID-19 pandemic.

Significant advancements in the field are underscored by recent product launches. Immunexpress launched the SeptiCyte Rapid test in the U.S. in February 2023, which can detect sepsis within an hour, facilitating faster medical responses. In August 2022, BD and Accelerate Diagnostics formed a collaboration to boost the efficiency of sepsis diagnostics, reflecting ongoing efforts to enhance the speed and accuracy of these diagnostics.

Additional innovations include Beckman Coulter’s DxH 690T hematology analyzer, designed as an early indicator of sepsis, and Prenosis Inc.’s expanded partnership with Roche Diagnostics to integrate AI into sepsis diagnostics. Furthermore, the FDA is reviewing the De Novo application for NAVOY Sepsis by AlgoDx, a clinical decision support software intended to predict sepsis in ICU patients, aiming to improve clinical decision-making.

In support of sepsis management, the CDC initiated the Hospital Sepsis Program Core Elements in August 2023. This program provides a framework for hospitals to enhance care and increase survival rates. These programs and technological innovations are crucial in decreasing mortality and improving outcomes, showing a strong commitment within the healthcare sector to effectively address this critical condition.

Key Takeaways

• The global sepsis diagnostics market is poised to reach USD 1,392.8 million by 2032, growing at a CAGR of 8.5%.
• Sepsis diagnostics encompass clinical assessments, lab tests, and imaging techniques to diagnose sepsis, a critical response to infection.
• Market growth is driven by increasing sepsis cases, an aging population, hospital-acquired infections, rising pneumonia cases, and new diagnostic technologies.
• Governments worldwide are increasing investments in infectious disease research, with a focus on sepsis.
• Diagnostic challenges include the inaccuracy of tests, high costs, and lengthy procedures.
• The COVID-19 pandemic has heightened the need for rapid sepsis diagnostics due to increased sepsis rates.
• Blood culture media leads product types with a 39% market share, while diagnostic instruments are set for rapid growth.
• Bacterial infections dominate sepsis diagnostics, holding 75% of the market, with fungal infections also in demand.
• Conventional diagnostic methods lead with a 54% share, but automated diagnostics are expected to expand significantly.
• Microbiology techniques hold a 45% market share; however, molecular diagnostics are growing swiftly.
• Hospitals and clinics are the primary end users, representing 71% of the market, with pathology labs also expanding.
• North America leads the regional market with a 41% share, while the Asia Pacific region is anticipated to see rapid growth.

Sepsis Diagnostics Statistics

• Diagnostic Accuracy: The assay for detecting sepsis boasts a 97% sensitivity and 98% specificity, demonstrating high reliability in diagnosing the condition.
• Pathogen Removal Efficiency: This device is capable of processing up to 1.25 liters of blood per hour, removing over 90% of pathogens, as evidenced in rat studies.
• Bacterial Separation Technique: The method achieves over 80% bacterial separation from whole blood through size-based separation techniques, eliminating the need for labeling.
• Mortality Rates by Sepsis Severity:
  • General sepsis fatalities stand at approximately 17%.
  • Mortality rates for severe sepsis or septic shock range from 40% to 60%.
  • Patients with no organ damage from sepsis have a mortality rate between 15% and 30%.
• Prognostic Impact of Sepsis Subtyping: Precise sepsis subtyping and tailored care pathways can lead to a prognostic difference of about 20% in patient outcomes.
• Trend in Sepsis Mortality Rates: Over the past decade, sepsis mortality rates have increased, with most healthcare organizations reporting rates between 19% and 30%.
• ICU Impact and Mortality: Despite occupying only 10% of ICU beds, sepsis is the leading cause of death among ICU patients.
• Hospital Admissions and Mortality:
  • Sepsis accounts for 6% of all hospital admissions.
  • It is also the leading cause of in-hospital deaths, accounting for 35% of such cases.
  • Treatment Delay Consequences: Delays in sepsis treatment increase mortality by 4% to 9% for each hour of delay.
• Economic Burden of Sepsis:
  • The U.S. annually spends approximately $38 billion on sepsis treatment.
  • The costs associated with sepsis treatment rise by about 8% each year.
  • Personal Impact of Sepsis: About 33% of surveyed individuals reported personal or familial experiences with sepsis.
• Challenges with Blood Culture Contamination:
  • Nearly 40% of hospital blood cultures are false positives due to contamination.
  • Contaminated blood cultures have an 8% mortality rate, nearly double the 4.6% rate for true negative controls.
  • Blood culture contamination rates were reduced from 2.6% to 1.8% during a 12-month period through best practices, as observed by the Hawthorne effect.
  • The use of Steripath led to an 88% reduction in blood culture contamination.
  • Removal of Steripath saw contamination rates rebound to 2.8%, a 93% increase from intervention levels.
  • Clinical studies have shown reductions in blood culture contamination ranging from 75% to 100%.
  • Adoption of Steripath resulted in a 31% reduction in vancomycin days of therapy.
  • Steripath guarantees at least a 50% reduction in blood culture contamination rates or offers a refund.
• Statistics on Venous Ulcers in the U.S.:
  • Venous ulcers account for 70-90% of all lower leg ulcers.
  • Annually, around 600,000 cases of venous ulcers are reported.
  • These ulcers result in a loss of 2 million workdays each year.
  • Among individuals aged 65 and older, 1.69% are affected by venous leg ulcers.

Emerging Trends

• Development of Biomarkers: Recent strides in sepsis diagnostics have been geared towards creating precise biomarkers. Focus is being placed on proteomic signatures which analyze unique protein patterns reflecting a patient’s immune response to sepsis. These signatures are key in understanding diverse clinical symptoms and in predicting disease outcomes with greater accuracy. Such advancements mark a shift towards more personalized diagnostic methods, allowing for treatments to be more specifically tailored.
• Advancements in Molecular Diagnostics: The scope of sepsis diagnostics is broadening with enhancements in genomic and molecular diagnostic techniques. A notable breakthrough is the SUSPECTS diagnostic platform, which uses suppression PCR-based selective enrichment sequencing to improve the detection of pathogens responsible for sepsis. This method is particularly effective in distinguishing between viral and bacterial infections, which is crucial for minimizing unnecessary antimicrobial use and enhancing patient care, as reported by BioMed Central.
• Incorporation of Machine Learning: Machine learning is increasingly being incorporated into sepsis diagnostics, significantly boosting the accuracy of predicting patient outcomes. By processing extensive datasets, machine learning algorithms can pinpoint key indicators such as specific biomarkers and clinical parameters critical for predicting sepsis mortality. This adoption of a data-driven approach in diagnostics is poised to revolutionize the prediction and management of sepsis in healthcare settings.

Use Cases

• Early Detection of Sepsis: Rapid diagnostic tools are essential for the early detection of sepsis, helping to prevent its progression to more severe stages such as septic shock. Biomarkers like procalcitonin and C-reactive protein are critical in this early identification process. These tools enable healthcare providers to swiftly assess patients for signs of sepsis, facilitating quicker access to necessary treatments.
• Optimizing Treatment: Advanced molecular diagnostics play a vital role in pinpointing specific pathogens responsible for sepsis. This precision allows for a more targeted treatment approach, improving the effectiveness of therapies and reducing the indiscriminate use of antibiotics. Such specificity helps lower the risk of antimicrobial resistance, aligning treatment more closely with the actual needs of the patient.
• Forecasting Patient Outcomes: The use of predictive analytics and machine learning in sepsis diagnostics significantly enhances the ability to predict patient outcomes. Tools that analyze data from various sources, including the Sequential Organ Failure Assessment (SOFA) score, vital signs, and laboratory results, can predict mortality risks and improve the management of resources in intensive care settings. This assists in making informed decisions about patient care, prioritizing interventions based on predicted severity.
• Personalized Sepsis Treatment: As understanding of biomarkers deepens, sepsis treatment is becoming increasingly personalized. Diagnostic advancements enable treatments to be customized according to the specific biomarker profiles and overall health conditions of individual patients. This personalized approach aims to increase survival rates and reduce complications by ensuring patients receive the most appropriate treatments tailored to their unique needs.

Conclusion

The sepsis diagnostics market is experiencing significant growth, driven by advancements in diagnostic technologies, evolving guidelines, and increasing global focus on combating sepsis. Innovative tools like biomarkers, AI-driven solutions, and molecular diagnostics enhance early detection, optimize treatments, and improve patient outcomes. Initiatives such as the Surviving Sepsis Campaign and CDC programs emphasize rapid response and patient-centered care. Despite challenges like high costs and diagnostic inaccuracies, the integration of new technologies and strategic collaborations promise substantial improvements. With a projected market size of USD 1,392.8 million by 2032 and a CAGR of 8.5%, sepsis diagnostics represents a pivotal healthcare domain.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF